Literature DB >> 22120187

Successful treatment of a woman with relapsing neuromyelitis optica by interferon beta.

Yan Xu1, Yao Zhang, Jing Ye, Bin Peng, Jian-Ming Wang, Li-Ying Cui.   

Abstract

Neuromyelitis optica (NMO) is an antibody-mediated disease with the target antigen being the water channel aquaporin-4 (AQP4). More than 90% of NMO patients have relapse. Optimal treatments to prevent recurrence have not been established. Previous reports suggest that interferon beta (IFNB) has not been effective in NMO. However, we present a case of NMO with positive anti-myelin oligodendrocyte glycoprotein (MOG)(27-38) IgG and anti-AQP4 IgG treated with IFNB-1a successfully. The effect of IFNB on NMO and the role of anti-MOG antibodies in NMO deserve further study.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22120187     DOI： 10.1007/s10072-011-0849-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  15 in total

1.  Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients.

Authors:  M H Rep; H M Schrijver; T van Lopik; R Q Hintzen; M T Roos; H J Adèr; C H Polman; R A van Lier
Journal:  J Neuroimmunol       Date:  1999-04-01       Impact factor: 3.478

2.  Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.

Authors:  T Saida; K Tashiro; Y Itoyama; T Sato; Y Ohashi; Z Zhao
Journal:  Neurology       Date:  2005-02-22       Impact factor: 9.910

3.  Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.

Authors:  P H Lalive; T Menge; I Barman; B A Cree; C P Genain
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

4.  Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.

Authors:  A Uzawa; M Mori; S Hayakawa; S Masuda; S Kuwabara
Journal:  Eur J Neurol       Date:  2009-12-21       Impact factor: 6.089

5.  Antineutrophil cytoplasmic antibodies and the optic-spinal form of multiple sclerosis in Japan.

Authors:  T Fukazawa; T Hamada; S Kikuchi; H Sasaki; K Tashiro; S Maguchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

Review 6.  Interferon-β exacerbates Th17-mediated inflammatory disease.

Authors:  Robert C Axtell; Chander Raman; Lawrence Steinman
Journal:  Trends Immunol       Date:  2011-04-29       Impact factor: 16.687

7.  Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.

Authors:  C G Haase; S Schmidt
Journal:  Neurosci Lett       Date:  2001-07-13       Impact factor: 3.046

8.  Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4.

Authors:  R Furlan; A Bergami; R Lang; E Brambilla; D Franciotta; V Martinelli; G Comi; P Panina; G Martino
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

9.  Interferon-beta(1b) treatment in neuromyelitis optica.

Authors:  Masami Tanaka; Keiko Tanaka; Mika Komori
Journal:  Eur Neurol       Date:  2009-07-07       Impact factor: 1.710

10.  Devic's syndrome: antibody to glial fibrillary acidic protein in cerebrospinal fluid.

Authors:  C H Chou; F C Chou; W W Tourtellotte; R F Kibler
Journal:  Neurology       Date:  1984-01       Impact factor: 9.910
View more
  1 in total

1.  Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.

Authors:  Satoru Oji; Eva-Maria Nicolussi; Nathalie Kaufmann; Bleranda Zeka; Kathrin Schanda; Kazuo Fujihara; Zsolt Illes; Charlotte Dahle; Markus Reindl; Hans Lassmann; Monika Bradl
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.